Market cap
$266 Mln
Recently Viewed
Clear AllMarket cap
$266 Mln
Revenue (TTM)
$48 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.3
Debt to Equity
0
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
53,228,300
CFO
$-1,032.99 Mln
EBITDA
$-1,045.46 Mln
Net Profit
$-1,425.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
| 70.1 | 0.2 | 91.6 | 14.2 | -26.0 | -- | -- |
|
BSE Sensex*
| -8.7 | 5.4 | -7.7 | -4.0 | 8.1 | 9.7 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
2seventy bio (TSVT)
| -30.9 | -54.4 | -63.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
|
5.0 | 266.1 | 48.4 | -4.1 | -122.7 | -1.9 | -- | 1.2 |
| 0.0 | 0.0 | 25.5 | -7.3 | -63.5 | -129.3 | -- | 0.0 | |
| 2.0 | 3.7 | 0.1 | -12.4 | -10,272.1 | -352.5 | -- | 9.9 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell... product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Read more
President & Director
Mr. Nick Leschly
President & Director
Mr. Nick Leschly
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of 2seventy bio Inc (TSVT) is $5.00 (NASDAQ) as of 22-May-2025 09:30 EDT. 2seventy bio Inc (TSVT) has given a return of -26.02% in the last 3 years.
Since, TTM earnings of 2seventy bio Inc (TSVT) is negative, P/E ratio is not available.
The P/B ratio of 2seventy bio Inc (TSVT) is 1.24 times as on 22-May-2025, a 71 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.69
|
0.73
|
|
2023
|
-1.01
|
0.86
|
|
2022
|
-1.41
|
1.16
|
|
2021
|
-2.09
|
1.70
|
|
2020
|
--
|
--
|
The 52-week high and low of 2seventy bio Inc (TSVT) are Rs 5.30 and Rs 2.29 as of 04-May-2026.
2seventy bio Inc (TSVT) has a market capitalisation of $ 266 Mln as on 22-May-2025. As per SEBI classification, it is a Small Cap company.
Before investing in 2seventy bio Inc (TSVT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.